The G-Tech Medical team discusses the impact of early funding on their “EKG for the gut,” exciting data emerging from current studies and growing interest from researchers and industry.
Our Health grantmaking aims to advance game-changing research that has the potential to improve the lives of people with IBD so it’s thrilling when our grantees gain recognition or high-profile journals publish their findings.
We welcomed students, academic and industry researchers, clinicians, funders and editors of science and health journals to our 2022 virtual Innovations Symposium.
Grantees are testing novel ideas from bright light therapy to diet and the gut-brain connection in the hopes of discovering new ways to reduce the risk of flare-ups and improve the lives of patients with IBD.
The Foundation’s Scientific Advisory Board is a dynamic mix of leading researchers and key strategic partners who provide essential guidance and scientific expertise to our Health Program.
Two of our grantees illustrate distinct and shared ways that the pandemic has disrupted biomedical research and affected the scientific community.
In July 2021, our Symposium convened online, allowing more people than ever to participate and hear from experts working across disciplines.
The Foundation made an early Program Related Investment to support Thetis Pharmaceuticals development of a novel therapy for ulcerative colitis, which just reached a new regulatory milestone.
Prominent journals featured cutting-edge advances by five grantees whose research focuses diagnostics, new therapies and biomarkers of mucosal healing that serve patients directly.
We’ve begun a journey of inquiry into the role that the Rainin Foundation can play to address racial disparities in the biomedical enterprise.